| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCL2A1 |
| Uniprot No | Q16548 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMTDCEF GYIYRLAQDY LQYVLQIPQP GSGPSKTSRV LQKVAFSVQK EVEKNLKSCL DNVNVVSVDT ARTLFNQVME KEFEDDIINW GRIVTIFAFE GILIKKLLRQ QIAPDVDTYK EISYFVAEFI MNNTGEWIRQ NGGWENGFVK KFEPKS |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCL2A1重组蛋白的3篇示例参考文献(注：文献标题与作者为示例性内容，建议通过学术数据库核实真实文献)：
1. **文献名称**：*"Recombinant BCL2A1 protein suppresses apoptosis by interacting with pro-apoptotic BCL-2 family members"*
**作者**：Smith J, et al.
**摘要**：研究通过大肠杆菌表达重组BCL2A1蛋白，证实其通过结合BAX/BAK等促凋亡蛋白抑制线粒体途径凋亡，揭示了其在癌症细胞耐药性中的作用。
2. **文献名称**：*"Structural characterization of recombinant BCL2A1 and its interaction with small-molecule inhibitors"*
**作者**：Chen L, et al.
**摘要**：利用X射线晶体学解析重组BCL2A1的三维结构，并筛选小分子抑制剂，为靶向BCL2A1的抗癌药物开发提供结构基础。
3. **文献名称**：*"Functional analysis of BCL2A1 mutants in regulating NF-κB signaling pathway"*
**作者**：Wang Y, et al.
**摘要**：通过重组BCL2A1蛋白及突变体实验，证明其通过调控NF-κB通路影响炎症反应和肿瘤细胞存活，揭示新型治疗靶点。
建议通过PubMed或Google Scholar搜索关键词“BCL2A1 recombinant protein”获取更多真实文献。
BCL2A1. a member of the BCL-2 protein family, is a critical regulator of apoptosis with distinct roles in cellular survival and stress responses. It encodes an anti-apoptotic protein characterized by conserved BCL-2 homology (BH) domains, primarily BH1. BH2. and BH4. which mediate interactions with pro-apoptotic family members like BAX and BAK. Unlike other anti-apoptotic BCL-2 proteins, BCL2A1 exhibits tissue-specific expression, prominently in hematopoietic cells, neutrophils, and activated lymphocytes, linking it to immune regulation and inflammatory processes. Its overexpression is associated with cancer cell survival, chemoresistance, and poor prognosis in malignancies such as melanoma, breast cancer, and leukemia.
Recombinant BCL2A1 protein is engineered for functional and structural studies to dissect its role in apoptosis evasion and disease mechanisms. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), the recombinant protein retains post-translational modifications when expressed in eukaryotic systems, enhancing its biological relevance. It serves as a tool for binding assays, inhibitor screening, and structural biology (e.g., crystallography) to identify therapeutic targets. Researchers also use it to study interactions with BH3-only proteins or small-molecule inhibitors like ABT-263. aiming to overcome treatment resistance in cancers.
The development of BCL2A1-targeted therapies remains challenging due to structural similarities across BCL-2 family members. Nonetheless, recombinant BCL2A1 provides a platform for elucidating its unique binding preferences and designing selective inhibitors, offering potential strategies to disrupt cancer cell survival pathways or modulate immune-related diseases. Its study continues to advance our understanding of apoptotic regulation in both physiological and pathological contexts.
×
